Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Keelung City 20401, Taiwan.
School of Traditional Chinese Medicine, Chang Gung University, Taoyuan City 33302, Taiwan.
Mar Drugs. 2022 Apr 10;20(4):261. doi: 10.3390/md20040261.
Freshwater clam extract (FCE) is a functional food that regulates the immune system and has been demonstrated in numerous studies to display desirable anti-tumor necrosis factor-alpha (TNF-α) responses. In addition, excess TNF-α production is positively associated with type 2 diabetes. However, few longitudinal clinical studies evaluating the efficiency and toxicity of FCE are available. This article reports that patients with prediabetes who received FCE had a desirable outcome of a reduction in serum TNF-α for a long period. This was a double-blind, randomized, parallel clinical trial conducted using FCE intervention and placebo groups, and 36 patients with prediabetes were enrolled. Two grams of FCE or placebo was consumed daily for 180 consecutive days. The serum of the participants was collected at four time points (0M: before the intervention; 3M: after 3 months of intervention; 6M: after 6 months of intervention; 12M: 6 months after cessation of intervention at 6M). A serum TNF-α concentration higher than 4.05 pg/mL was defined as a cut-off value. FCE reduced serum TNF-α in all participants at 6M and 12M. Moreover, FCE significantly suppressed serum TNF-α concentrations at 6M and 12M and inhibited TNF-α release with time series in subjects with elevated TNF-α values. FCE intervention effectively reduced serum TNF-α and persistently sustained the effects for half a year in patients with prediabetes. Gas chromatography-mass spectrometry (GS-MS) analysis revealed that the major components of FCE were phytosterols and fatty acids, which exerted anti-inflammatory and anti-TNF-α abilities. Hence, FCE has the potential to be developed as a natural treatment for prediabetic patients in Taiwan.
淡水贝类提取物 (FCE) 是一种调节免疫系统的功能性食品,已有大量研究表明其具有理想的抗肿瘤坏死因子-α (TNF-α) 作用。此外,过量的 TNF-α 产生与 2 型糖尿病呈正相关。然而,目前可用的评估 FCE 疗效和毒性的纵向临床研究较少。本文报道了接受 FCE 治疗的糖尿病前期患者在很长一段时间内血清 TNF-α水平降低的理想结果。这是一项使用 FCE 干预和安慰剂组进行的双盲、随机、平行临床试验,共纳入 36 例糖尿病前期患者。每天服用 2 克 FCE 或安慰剂,连续 180 天。在四个时间点采集参与者的血清(0M:干预前;3M:干预 3 个月后;6M:干预 6 个月后;12M:干预 6 个月后 6 个月停止干预时)。将血清 TNF-α浓度高于 4.05 pg/mL 定义为截断值。FCE 可降低所有参与者在 6M 和 12M 时的血清 TNF-α水平。此外,FCE 可显著抑制 6M 和 12M 时的血清 TNF-α浓度,并随着时间的推移抑制 TNF-α释放,对于 TNF-α 值升高的受试者。FCE 干预可有效降低糖尿病前期患者的血清 TNF-α水平,并持续半年以上维持疗效。气相色谱-质谱联用分析 (GS-MS) 显示,FCE 的主要成分是植物甾醇和脂肪酸,具有抗炎和抗 TNF-α作用。因此,FCE 有可能开发成为台湾地区糖尿病前期患者的天然治疗方法。